Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.
The XXVII Annual Chemotherapy Foundation Symposium sponsored by The Mount Sinai School of Medicine is one of the leading forums for communication of important discoveries and new developments in cancer therapeutics. Here, we summarize and review the emerging advances in the treatment of breast cancer, which includes therapeutics in HER signaling, poly(ADP-ribose) polymerase inhibition, PI3K inhibitors and novel epithilones.
Barginear
Myra F
MF
Division of Hematology and Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1079, NY 10029, USA. myra.barginear@mssm.edu
Raptis
George
G
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors